Back

Small molecule oxybutynin rescues proliferative capacity of complex III-defective MPCs

Qu, Y.; Edwards, K.; Li, M.; Liu, Y.; Tsai, P.-Y.; Cheng, C.; Blum, J.; Acor, N.; Oshoe, T.; Rooney, K.; Walter, C.; Thirumlaikumar, V. P.; Thalacker-Mercer, A.; Skirycz, A.; Barrow, J.

2024-11-09 cell biology
10.1101/2024.11.08.622694 bioRxiv
Show abstract

Mitochondrial disease encompasses a group of genetically inherited disorders hallmarked by an inability of the respiratory chain to produce sufficient ATP. These disorders present with multisystemic pathologies that predominantly impact highly energetic tissues such as skeletal muscle. There is no cure or effective treatment for mitochondrial disease. We have discovered a small molecule known as oxybutynin that can bypass Complex III mitochondrial dysfunction in primary murine and human skeletal muscle progenitor cells (MPCs). Oxybutynin administration improves MPC proliferative capacity, enhances cellular glycolytic function, and improves myotube formation. Mechanistically, results from our isothermal shift assay indicates that oxybutynin interacts with a suite of proteins involved in mRNA processing which then trigger the upregulation biological pathways to circumvent CIII mitochondrial dysfunction. Taken together, we provide evidence for the small molecule oxybutynin as a potential therapeutic candidate for the future treatment of CIII mitochondrial dysfunction.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.